acetylcysteine oral / Generic mfg. - LARVOL DELTA

Effect of high-dose N-acetyl cysteine on the clinical outcome of patients with diabetic peripheral neuropathy: a randomized controlled study. (PubMed, Diabetol Metab Syndr) - P4 | "High dose NAC administered for 12 weeks modulated inflammation by reducing TNF-alpha and increasing GPx and NRF2 versus controls. NAC improved clinical outcomes of DPN reflected by a decline in neuropathy and pain scores and an improvement in QOL."

Clinical • Clinical data • Journal • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Mood Disorders • Oncology • Pain • Peripheral Neuropathic Pain • Psychiatry • TNFA

N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings. (PubMed, Neuropsychopharmacology) - P2/3 | "Treatment-seeking youth with cannabis use disorder (N = 192, ages 14-21) were randomized to receive a double-blind 12-week course of oral N-acetylcysteine 1200 mg or placebo twice daily; all received weekly medical management and brief behavioral counseling. More N-acetylcysteine than placebo treated participants reported gastrointestinal adverse events (63/98 versus 37/94, χ21 = 11.9 p < 0.001); adverse events were otherwise similar between groups. Findings indicate that N-acetylcysteine is not efficacious for youth cannabis use disorder when not paired with contingency management, highlighting the potentially crucial role of a robust behavioral treatment platform in facilitating prior positive efficacy findings with N-acetylcysteine.Trial Registration: Clinicaltrials.gov identifier NCT03055377."

Journal • Gastrointestinal Disorder • Substance Abuse

The Safety and Effectiveness of Taneasy and Actein in COPD Patients (clinicaltrials.gov) - P4 | N=42 | Completed | Sponsor: Bun Yao Biotechnology Co., Ltd | Enrolling by invitation ➔ Completed | N=60 ➔ 42

Enrollment change • Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Retrospective Review of Oral N-Acetylcysteine for Habit-Driven Cutaneous Disorders. (PubMed, Pediatr Dermatol) - "We retrospectively evaluated the therapeutic use and safety of oral NAC in 93 children from the Children's Hospital of Philadelphia. This study supports the use of oral NAC for habit-driven skin, hair, and nail abnormalities in pediatric patients."

Journal • Retrospective data • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry

Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (clinicaltrials.gov) - P2/3 | N=180 | Recruiting | Sponsor: Ain Shams University | Not yet recruiting ➔ Recruiting

Enrollment open

The Safety and Effectiveness of Taneasy and Actein in COPD Patients (clinicaltrials.gov) - P4 | N=60 | Enrolling by invitation | Sponsor: Bun Yao Biotechnology Co., Ltd

New P4 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Oral N-acetylcysteine ameliorates liver fibrosis and enhances regenerative responses in Mdr2 knockout mice. (PubMed, Sci Rep) - "Spatial protein analysis revealed cell-type specific differential response to NAC, collectively indicating a transition from pro-apoptotic into proliferative state. NAC treatment should be further investigated as a potential therapeutic option for human cholangiopathies."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • ABCB4

Watch Out for Off-Label Weight Loss Medication Use: Zonisamide-Induced Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Drug Induced Liver Injury (ACG 2024) - "She received intravenous (IV) n-acetylcysteine, oral ursodiol, and daily IV methylprednisolone...Dupilumab was initiated to help wean prednisone and cyclosporine...G. Liver chemistries over clinical course."

Cardiovascular • Cholestasis • Dermatitis • Dermatology • Eosinophilia • Hematological Malignancies • Hepatology • Hodgkin Lymphoma • Hypertension • Immunology • Infectious Disease • Liver Failure • Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Septic Shock

Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity (clinicaltrials.gov) - P2/3 | N=180 | Not yet recruiting | Sponsor: Ain Shams University

New P2/3 trial

Oral N-Acetylcysteine Use for Acetaminophen Toxicity in an Infant (AAP-NCE 2024) - "Oral NAC is a safe and effective means to treat acetaminophen toxicity in pediatric patients in many cases. Oral therapy should be considered in cases where a patient may be at higher risk of complications of IV therapy such as hyponatremia or volume overload. This case demonstrates a positive outcome with oral NAC therapy and no adverse effects from treatment."

Cardiovascular • Heart Failure • Pediatrics

Lack of efficacy of oral N-acetylcysteine ​​in the treatment of facial melasma in women: a randomized, double-blind, placebo-controlled clinical trial. (PubMed, An Bras Dermatol) - No abstract available

Clinical • Journal • Dermatology • Dermatopathology

A new meaning to "picking your nose": The first use of N-acetylcysteine to successfully treat trigeminal trophic syndrome. (PubMed, Clin Exp Dermatol) - "We present a case of trigeminal trophic syndrome in an elderly lady who successfully responded to oral N-acetylcysteine. An increased awareness of this rare syndrome and potential treatment options will encourage a prompt diagnosis and possibly prevent permanent disfiguration."

Journal • Cardiovascular

Impact of Thermo-Responsive N-Acetylcysteine Hydrogel on Dermal Wound Healing and Oral Ulcer Regeneration. (PubMed, Int J Mol Sci) - "The study concludes that modifying viscosity enhances NAC retention, facilitating tissue regeneration. These findings support previous research on the beneficial effects of antioxidant application on damaged tissues, suggesting the potential of NAC hydrogels in improving wound care and oral ulcer treatment."

Journal • Inflammation

Comparison of therapeutic effects of N-Acetylcysteine with pregabalin in improving the clinical symptoms of painful diabetic neuropathy: a randomized, double-blind clinical trial. (PubMed, Clin Diabetes Endocrinol) - "NAC is efficacious in alleviate symptoms of PDN which is probably related to its antioxidant effects."

Clinical • Journal • Diabetes • Diabetic Neuropathy • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus • CAT

N-Acetylcysteine for Adolescent Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=120 | Completed | Sponsor: Medical University of South Carolina | Active, not recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ Feb 2024

Trial completion • Trial completion date • Addiction (Opioid and Alcohol)

N-Acetylcysteine for Youth Cannabis Use Disorder (clinicaltrials.gov) - P2/3 | N=192 | Completed | Sponsor: Medical University of South Carolina | Active, not recruiting ➔ Completed

Trial completion • Substance Abuse

Comparative Clinical Study to Evaluate the Possible Efficacy and Safety of Oral N-Acetyl Cysteine Versus Rectal Diclofenac in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (clinicaltrials.gov) - P1/2 | N=46 | Recruiting | Sponsor: Tanta University

New P1/2 trial • Pancreatitis • IL10 • TNFA

Oral NAC: Effect of Oral N-Acetyl Cysteine in Prevention of Necrotizing Enterocolitis in Preterm Neonates With Feeding Intolerance (clinicaltrials.gov) - P4 | N=100 | Active, not recruiting | Sponsor: Ain Shams University

New P4 trial • Gastrointestinal Disorder

Fifty years of paracetamol (acetaminophen) poisoning: the development of risk assessment and treatment 1973-2023 with particular focus on contributions published from Edinburgh and Denver. (PubMed, Clin Toxicol (Phila)) - "Thus, oral acetylcysteine became the antidote trialed in the United States National Multicenter Study...Even after 50 years, there are still areas of uncertainty. These include appropriate acetylcysteine doses in patients who ingest different paracetamol doses or multiple (staggered) ingestions, early identification of at-risk patients, and optimal treatment of late presenters."

Clinical • Journal • Review • Hepatology

NAC Attack: Oral N-acetylcysteine for Retinitis Pigmentosa (clinicaltrials.gov) - P3 | N=438 | Recruiting | Sponsor: Johns Hopkins University

Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial. (PubMed, Immun Inflamm Dis) - "The NAC could be more effective as prophylactic or adjuvant therapy in stable non-severe cases of COVID-19 with a particularly positive role in the augmentation of O saturation and faster reduction of the CRP level and inflammation or could be effective for better controlling of COVID-19 or its therapy-related side effects."

Clinical • Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • CRP

N-Acetylcysteine for Youth Cannabis Use Disorder (clinicaltrials.gov) - P2/3 | N=192 | Active, not recruiting | Sponsor: Medical University of South Carolina | Recruiting ➔ Active, not recruiting

Enrollment closed • Substance Abuse

N-Acetylcysteine for Adolescent Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: Medical University of South Carolina | Recruiting ➔ Active, not recruiting

Enrollment closed • Addiction (Opioid and Alcohol)

The potential antioxidant effect of N-acetylcysteine on X-ray ionizing radiation-induced pancreas islet cell toxicity. (PubMed, Biochem Biophys Res Commun) - "This study provides evidence for the beneficial effects of N-acetyl cysteine on islets of Langerhans cells with X-ray ionizing-radiation-induced damage in a rat model."

Journal • Hepatology • Oncology • CASP3

High dose oral N- Acetylcysteine in the treatment of bronchiectasis: A double-blind, randomised pilot study assessing anti-inflammatory and clinical outcomes in adults (APSR 2023) - No abstract available

Clinical • Clinical data • Bronchiectasis • Pulmonary Disease • Respiratory Diseases